Research programme: brain development disorder therapeutics - Seaside Therapeutics

Drug Profile

Research programme: brain development disorder therapeutics - Seaside Therapeutics

Alternative Names: mGluR5 antagonists - Seaside; muscarinic M1 receptor antagonists - Seaside; STX 110

Latest Information Update: 21 Jun 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Seaside Therapeutics
  • Class
  • Mechanism of Action Metabotropic glutamate receptor 5 antagonists; Muscarinic M1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Autistic disorder; Fragile X syndrome

Most Recent Events

  • 31 Dec 2011 Preclinical development is ongoing for Fragile X syndrome and Autism in the US
  • 05 Feb 2008 Preclinical trials in Fragile X syndrome in USA (unspecified route)
  • 19 Sep 2006 Preclinical trials in Autism in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top